1. Araujo AR, Rosso N, Bedogni G, Tribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018 Feb;38 Suppl 1:47-51. doi: 10.1111/liv.13643.
2. Chopra S, lai M. Natural history and management of nonalcoholic fatty liver disease in adults. UpToDate [Online]. 2024. Available from URL: https://www.uptodate.com/contents/management-of-nonalcoholic-fatty-liver-disease-in-adults#H1.
3. EASL–EASD–EASO Clinical Practice Guidelines for the management
of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.
4. Younossi ZM. Non-alcoholic fatty liver disease-A global public health perspective. J Hepatol. 2019 Mar;70(3):531-544. doi: 10.1016/j.jhep.2018.10.033.
5. Younossi ZM et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431.
6. Leoni S et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systemic review with comparative analysis. World J Gastroenterol. 2018; 24(30): 3361–3373. doi: 10.3748/wjg.v24.i30.3361
7. Gomez MR, Sagi SZ, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017 Oct;67(4):829-846. doi: 10.1016/j.jhep.2017.05.016.
8. Kwak MS, Kim DH. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med 2018;33:64-74 https://doi.org/10.3904/kjim.2017.343
9. Said A, Akhter A. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. Annals of Hepatology 2017:16(4):538-47. DOI: 10.5604/01.3001.0010.0284
10. Younossi, Z. M., Marchesini, G., Pinto-Cortez, H., & Petta, S. (2018). Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Transplantation, 1. doi:10.1097/tp.0000000000002484
11. Sanyal AJ et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 2010; 362:1675-1685 DOI: 10.1056/NEJMoa0907929
12. El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth?. Antioxidants. 2018;7(1):12. doi:10.3390/antiox7010012
13. Thendiono E. The Effect of Vitamin E (Mixed Tocotrienol) on the Liver Stiffness Measurement Measured by Transient Elastography (Fibroscan) among NAFLD Patients. Gut 2018;67(Suppl 2):A1–A118 http://dx.doi.org/10.1136/gutjnl-2018-IDDFabstracts.189
14. Magosso E et al. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Magosso et al. Nutrition Journal 2013, 12:166 http://www.nutritionj.com/content/12/1/166
15. Sanchez PP, Cusi K. Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Clinical Diabetes and Endocrinology 2016;2:9 https://doi.org/10.1186/s40842-016-0027-7
16. Manco M. Insulin Resistance and NAFLD: A Dangerous Liaison beyond the Genetics. Children (Basel). 2017;4(8):74. doi:10.3390 /children 4080074
17. Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011;4(4):249–263. doi:10.1177/1756283X11403809
18. Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsbøll T. Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. Front Endocrinol (Lausanne). 2018;9:649. Published 2018 Nov 6. doi:10.3389/fendo.2018.00649
19. Zhong S, Fan Y, Yan Q, et al. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore) ;96(49):e9061. doi:10.1097/MD.0000000000009061
20. Colica C, Boccuto L, Abenavoli L. Silymarin: An option to treat non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8437–8438. doi:10.3748/wjg.v23.i47.8437
21. Xiang Z et al. The role of Ursodeoxycholic Acid in Non-Alcoholic Steatohepatitis. BMC Gastroeneterol.2013:13(140). https://doi.org/ 10.1186/1471-230X-13-140
22. Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23(42):7495–7504. doi:10.3748/wjg.v23.i42.7495
23. Scorletti E, Bryne CD. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Mol Aspects Med. 2018 Dec;64:135-146. doi: 10.1016/j.mam.2018.03.001.
24. Neuschwander-Tetri BA, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65.
25. Ratzui V, et al. REGENERATE: a Phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis. J Hepatol. 2016;64(2):S214–5.
26. Abenavoli L et al. Obeticholic Acid: A New Era in the Treatment of Naonalcoholic Fatty Liver Disease. Pharmaceuticals 2018, 11, 104; doi:10.3390/ph11040104.